Vitamin D
Drug2400 IU/day by mouth for 16 weeks
Other names: Cholecalciferol
NCT Number: NCT02091219
The purpose of this study is to compare the effects of two different forms of vitamin D supplements (vitamin D3 and 25-hyrdroxyvitamin D3 [25(OH)D3]) on vitamin D levels in the blood, and on markers of skeletal and immune health. This study is designed as a pilot study. A multi-ethnic cohort of 48 patients will be included (12 Caucasian, 12 African American, 12 Hispanic/Latino, 12 Asian/Asian American). Potential study candidates will undergo a screening visit during which a medical history will be taken, a physical exam performed, a dietary questionnaire administered, and blood collected. The purpose of the screening visit is to identify vitamin D-deficient (25-hydroxyvitamin D <20 ng/ml) individuals who are candidates for vitamin D supplementation. Eligible patients will then be randomly assigned to receive either vitamin D3 (2400 IU/day) or 25(OH)D3 (20 mcg/day) for 16 weeks. After initiating supplementation, study patients will return for follow-up visits at weeks 4, 8, and 16. At each visit, blood will be collected to assess vitamin D levels in the blood, as well as markers of skeletal and immune function. Participation in this study will therefore involve a total of 5 visits (1 screening visit, 1 randomization visit during which participants will receive their study supplements, 3 follow-up visits). After all data is collected, changes in vitamin D levels in the blood following supplementation with either vitamin D3 versus 25(OH)D3 will be determined, and correlated to markers of calcium balance and immune function. Knowledge gained from this study may have a significant impact on how vitamin D status is defined, and how vitamin D repletion is administered.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Early Phase 1
UCLA Clinical and Translational Research Center (CTRC), Los Angeles, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2400 IU/day by mouth for 16 weeks
Other names: Cholecalciferol
20 micrograms/day by mouth for 16 weeks
Other names: Calcifediol, HyD
Time frame: 16 weeks
Time frame: 16 weeks
Time frame: 16 weeks
Time frame: 16 weeks
Time frame: 16 weeks
Time frame: 16 weeks
Time frame: 16 weeks
Time frame: 16 weeks
Time frame: 16 weeks
University of California, Los Angeles
Other
The Effects of Vitamin D3 Versus 25OHD3 (HyD) on Serum Vitamin D Metabolites and Markers of Mineral Metabolism and Immune Function
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07631312
Anemia, Anemia, Hypochromic
Atlanta, Georgia, United States
View Trial DetailsNCT06700122
Avitaminosis, Deficiency Diseases
Cairo, Egypt
View Trial DetailsNCT06654063
Avitaminosis, Deficiency Diseases
Cairo, Egypt
View Trial DetailsNCT07481240
Avitaminosis, Deficiency Diseases
Cork, Co. Cork, Ireland
View Trial Details